# An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

> **NCT01328444** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 349 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GSK 573719 +GW642444 125/25
- **DRUG:** GSK573719 + GW642444 62.5/25
- **DRUG:** GSK 573719 125
- **DRUG:** GSK 573719 62.5
- **DRUG:** GW642444 25
- **DRUG:** Plb

## Key facts

- **NCT ID:** NCT01328444
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-01
- **Primary completion:** 2012-06-01
- **Final completion:** 2012-06-14
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328444, "An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01328444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*